Reference is made to the stock exchange notice on 6 June 2023 regarding an
agreement whereby Nordic Nanovector ASA (the "Company") would acquire all issued
shares in Thor Medical AS. On 28 June 2023 the annual general meeting of Nordic
Nanovector ASA approved the agreement and the parties have today completed the
transaction related thereto with the subscription of new shares in the Company
by shareholders of Thor Medical AS against contributing Thor Medical shares (the
"Transaction"). 

The following primary insider and close associates to primary insiders in Nordic
Nanovector, have purchased shares in the Company in connection with the
Transaction:

-	Alf Bjørseth, CEO of Nordic Nanovector, has subscribed 47,855 shares
-	Scatec Innovation AS, that is a legal person closely associated with John
Andersen Jr., who is a board member of Nordic Nanovector, has subscribed
57,151,062 shares.
-	Scatec Invest II AS, that is a legal person closely associated with John
Andersen Jr., who is a board member of Nordic Nanovector, has subscribed
1,584,324 shares.
-	Scatec Invest IV, that is a legal person closely associated with John Andersen
Jr., who is a board member of Nordic Nanovector, has subscribed 3,165,920
shares.

Please refer to the stock exchange notices made public by the Company on 6 June
2023, 28 June 2023 and 3 July 2023 for further information about the
Transaction.

Attached are the notifications of the transaction in accordance with the Market
Abuse Regulation Article 19.

For more information, please contact: 

Contacts

Ludvik Sandnes, chairman of the board of directors 
+47 907 43 017

This information is subject to the disclosure requirements pursuant to the
Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities
Trading Act.